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Abstract


Abstract

The thesis entitled, “Design, Synthesis and Biological Evaluation of Novel Pyrrolo[2,1-c][1,4]benzodiazepine Hybrids and Phenazine Analogues” has been divided into four chapters. Chapter I gives the general introduction about cancer chemotherapy, covalent, non-covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics and objectives of the present work. Chapter II consists of the design, synthesis and DNA-binding affinity of novel coumarin linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids and their antitumour activity against sixty human tumor cell lines. In Chapter III, Section A comprises of the synthesis, DNA binding affinity and in vitro cytotoxicity of nicotinamides and isonicotinamides linked pyrrolobenzo-diazepine hybrids. Section B describes the development of new methodology for the reduction of azides to amines and its applications in the synthesis of bioactive heterocyclic molecules. Chapter IV describes the design and synthesis of new phenazine analogues as antitubercular agents.

Chapter-I
GENERAL INTRODUCTION: 

Cancer is a disease caused by the malfunctioning of normal cells. Chemotherapy or the use of chemical agents to destroy the cancer cells is a mainstay in the treatment of malignancies. A major advantage of chemotherapy is its ability to treat widespread or metastatic cancer, whereas surgery and radiation therapies are limited to treating the cancers that are confined to specific area. The major categories of chemotherapeutic agents are antitumour antibiotics, topoisomerase I and II inhibitors, DNA interactive agents and other miscellaneous compounds. The first PBD antitumour antibiotic anthramycin has been described by Leimgruber et.al about 38 years back, and since then a number of compounds have been developed on PBDs as the basic scaffold leading to a number of DNA binding ligands. Pyrrolo[2,1-c][1,4]benzodiazepines have the potential as regulators of gene expression with possible therapeutic application in the treatment of genetic disorders, including cancer.
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are well known class  of antitumour antibiotics with sequence selective DNA binding ability that are derived from various Streptomyces species. Their mode of interaction with DNA has been extensively studied and it is considered unique as they bind within the minor groove of B form DNA. These compounds exert their biological activity by covalently binding to the C2-amino group of guanine residue in the minor groove of DNA through the imine or imine equivalent functionality at N10-C11 of the PBD moiety. 
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Chapter-II

Design, synthesis, DNA-binding affinity and in vitro cyto-
toxicity of NOVEL coumarin-LINKED Pyrrolo[2,1-c][1,4] benzo- diazepine hybrids

It has been of considerable interest in the past few years to design and synthesize symmetrical cross-linking agents, particularly based on pyrrolobenzodiazepines (PBDs). Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are of current interest due to their ability to recognize and subsequently form covalent bonds to specific base sequences of double stranded DNA. Pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics bind covalently to the N2 of guanine at purine-guanine-purine sites in the minor groove of DNA. 
Coumarins have attracted intense interest in recent years because of their diverse pharmacological properties. Among these properties, their cytotoxicity effects were most extensively examined. Some of the natural coumarins are found in a variety of plant sources. These compounds have demonstrated activity against prostrate cancer, malignant melanoma and metastatic renal cell carcinoma.
The objective of the present work is to combine the features of both alkylating and DNA binding properties in the same molecule. Therefore, it has been considered of interest to couple coumarin to the C8-position of the PBD through its piperazinyl amino functionality. In the present chapter the synthesis, DNA-binding affinity and in vitro cytotoxicity of the novel coumarin-PBD hybrids have been described.

Scheme 1 

	Synthesis of 4-piperazino-2H-2-chromenone has been carried out by employing 2-hydroxy acetophenone as the starting material. Condensation of 2-hydroxy acetophenone followed by cyclization using Na/diethylcarbonate gives the 4-hydroxy-2H-2-chromenone, which on further condensation with piperazine by literature methods yields compound 3 (Scheme 1).



Scheme 2



The key intermediates 9a-c have been prepared by using commercially available 2-methyl resorcinol, which upon Friedal Craft’s reaction gave the compound 5. Deacetalization of compound 5 followed by etherification with n-alkyl iodide produced 7a-c. The compounds 7a-c on condensation followed by cyclization with Na/diethylcarbonate gave the products 8a-c. Further, condensation of 8a-c produces 9a-c (Scheme 2).



Scheme 3




Synthesis of C8-linked coumarin-PBD hybrids has been carried out by employing the commercially available vanillin. Oxidation of vanillin followed by benzylation and nitration provided the 4-benzyloxy-5-methoxy-2-nitrobenzoic acid (10). L-Proline methyl ester has been coupled to 4-benzyloxy-5-methoxy-2-nitrobenzoic acid to afford the compound 11, which on further reduction of the ester group with DIABAL-H produced the corresponding aldehyde. This upon protection with EtSH/TMSCl gave 13, which upon debenzylation gave (2S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehydediethylthio- acetal (14) and with subsequent etherification by dibromoalkanes provided 15a-c. This compound has been coupled to compound 3 to produce 16a-c. These coupled nitrothioacetal intermediates 16a-c upon reduction with SnCl2.2H2O in methanol gave the aminothioacetal precursors 17a-c, and these on deprotection by HgCl2/CaCO3 afforded the desired PBD hybrids 18a-c (scheme 3).
























Scheme 4





The compounds 25a-c, 26a-c and 27a-c have been prepared by employing 15a-c as the starting materials. These were further treated with the respective substituted coumarin derivatives 9a-c to yield 19a-c, 20a-c and 21a-c respectively. These nitro derivatives have been further reduced with SnCl2.2H2O in methanol giving the corresponding aminothioacetal precursors 22a-c, 23a-c and 24a-c and these on deprotection with HgCl2/CaCO3 afforded the desired PBD hybrids 25a-c, 26a-c and 27a-c (scheme 4).
	These PBD hybrids have been tested against sixty human tumor cell lines from nine cancer types (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostrate cancer and breast cancer) as per NCI protocol. For each compound, dose response curves for individual cell lines have been measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug exposure has been used, and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration for 50% cell growth inhibition (GI50), total cell growth inhibition (TGI, 0% growth) and 50% cell death (LC50, -50% growth) compared with the control has been calculated. Among them 18c exhibits a wide spectrum of activity against forty one cell lines in nine cell panels, with GI50 value of <20 nM. In this study compound 18c exhibited cytotoxicity activity against renal and breast cancer panels with GI50 values (11.6-43.4 nM). Compound 25a exhibits activity against fifty-six cell lines in nine cancer cell panels with GI50 values of < 10 M. 
The DNA binding affinity of these novel PBD hybrids has been evaluated through thermal denaturation studies with duplex-form of calf thymus DNA (CT-DNA). Melting studies show that these compounds stabilize the thermal helix to coil transition of the CT-DNA efficiently. Interestingly, in this assay one of the coumarin-PBD hybrid (25c) elevates the helix melting temperature of CT-DNA by a margin of 17.5 C after incubation for 18 h at 37 C. 








Chapter IIi-section a

synthesis, DNA-binding affinity and in vitro cytotoxicity of NOVEL nicotinamide and isonicotinamide-LINKED Pyrrolo[2,1-c][1,4]benzodiazepine hybrids

Minor groove binding ligands and their derivatives have shown a wide range of biological activity as antitumour, antiviral, antifungal and antimicrobial agents. Their mode of action is to involve initially the minor groove binding of the DNA and possibly followed by interference in the function of DNA topoisomerases. Nicotinamide and isonicotinamide derivatives constitute a broad class of bioactive molecules. These compounds are used as fungicides, pesticides or for treatment of benign prostatic hyperplasia. Many administrations of nicotinamide suggested the therapeutic interest in preventing the development of stroke by rescuing the still viable but injured cells and partially preventing infarction. These are also used for treating AIDS, inflammatory allergic and respiratory diseases. They also prevent the neuronal and vascular cell injury. Nicotinamide derivatives act as anti-diabetogenic agents.
The objective of the present work describes the biological activities of the nicotinamides, isonicotinamides and pyrrolo[2,1-c][1,4]benzodiazepines
















Scheme 5.


Synthesis of nicotinamide-PBD hybrids has been carried out by employing the (2S)-N-[4-(n-bromoalkyl)oxy-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carbo-xaldehyde diethylthioacetal as the starting materials (15a-c). These compounds were further treated with N-Boc piperazine to give the compounds 28a-c, which on further Boc deprotecton followed by coupling with nicotinoyl chloride give the products 29a-c. These nitro compounds upon reduction with SnCl2.2H2O in methanol gave the aminothioacetal precursors 30a-c and these on deprotection with HgCl2/CaCO3 to afford the desired PBD-hybrids 31a-c (Scheme 5).






Scheme 6


The precursors 28a-c have been prepared according to the above procedure. These compounds on further Boc deprotecton followed by coupling with isonicotinoyl chloride give the products 29d-f. These nitro compounds upon reduction with SnCl2.2H2O in methanol give the aminothioacetal precursors 30d-f and these on deprotection with HgCl2/CaCO3 affords the desired PBD-hybrids 31d-f (Scheme 6).
Compounds 31a, 31b and 31e have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines of colon (Colo205), lung (Hop-62), cervix (SiHa), prostrate (DU145, PC3), oral (DWD, HT1080), and breast (MCF7, Zr-75-1) origin. A protocol of 48 h continuous drug exposure and an adriamycin (ADR) protein assay has been used to estimate cell viability or growth. The results are expressed as percent of cell growth determined relative to that of untreated control cells. Compound 31e showed promising cytotoxicity against some cancer cell lines.


The DNA binding activity for these novel C8 linked nicotinamide and isonicotinamide-PBD hybrids has been examined by thermal denaturation studies using calf thymus (CT) DNA. Melting studies show that these compounds stabilize the thermal helix  coil or melting stabilization (Tm) for the CT-DNA duplex at pH 7.0, incubated at 37 C, where PBD/DNA molar ratio is 1:5. Interestingly in this assay one of the nicotinamide-PBD hybrids (31c) elevates the helix melting temperature of CT-DNA by a 4.5 C after incubation for 18 h at 37 C.

Chapter IIi-section b

REDUCTION OF AZIDES TO AMINES USING FeCl3/NaI: SYNTHESIS OF BIOACTIVE HETEROCYCLES


The reduction of azides to amines is an important reaction for the synthesis of a variety of organic compounds, which are useful in synthetic as well as medicinal chemistry. The azides can be easily prepared with good regio-, stereo- and enantioselectivity. The present approach has been carried out under extremely mild conditions to provide a novel and efficient chemoselective protocol for the reduction of alkyl, aryl and benzyl azides to their corresponding amines (Scheme 7).
Scheme 7









Scheme 8



In the present work an azidoreductive cyclization process to obtain pyrrolo[2,1-c][1,4]benzodiazepin-5,11-diones 33a-d and pyrrolo[2,1-c][1,4]benzodiazepines 34a-d employing FeCl3/NaI. Azidobenzoyl pyrrolidine esters 32a-d have been treated with DIBAL-H to obtain the corresponding aldehydes 33a-d. These upon reductive cyclization with FeCl3/NaI provided the corresponding pyrrolo[2,1-c][1,4]benzodiazepin-5,11-diones 33a-d and pyrrolo[2,1-c][1,4]benzodiazepines 34a-d in quantitative yields (Scheme 8)

Scheme 9




In the present work an azidoreductive cyclization process to obtain another important class of heterocycle skeletons with reported bronchodilator action viz., pyrrolo[2,1-b]quinazolinone system 38-40 employing FeCl3-NaI has been envisaged. This method has been further applied to the cyclization of similar substrates namely, the azidobenzoyl lactams 35-37, as shown in the Scheme 9 to obtain the corresponding pyrido- and azepino- quinazolinones 20-22. The appropriate precursors 2-azidobenzoyl lactams have been prepared by coupling 2-azidobenzoic acids with respective lactams. These upon reductive cyclization with FeCl3-NaI provided the corresponding [2,1-b]quinazolinones 38-40 in quantitative yields and these reactions have been monitored by TLC.

Chapter Iv
DESIGN AND SYNTHESIS OF NEW PHENAZINE ANALOGUES AS ANTITUBERCULAR AGENTS

Tuberculosis is a leading cause of death from a single infectious agent in the world. Approximately one third of the world’s population harbors latent TB, and three million are reported to die from its effects every year. This disease continues to be major health problem not only in India but also in many south asian countries. This is not only due to the lack of proper therapeutic agents for its treatment but also due to the development of drug-resistant strains. Additionally, patients infected with AIDS have a higher resistance of primary and reactivated TB thus increasing the risk of death. The present type of treatment for TB is much more difficult and may also become ineffective some times due to the emergence of multidrug resistant tuberculosis, thus leaving a need for the development of novel antitubercular agents. In this part of the work new analogues of phenazine have been designed and synthesized in pursuit of effective antitubercular agents.
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The compounds 41a-h have been prepared by refluxing the respective phthalimides and naphthalimides with a series of dibromoalkanes in dry acetonitrile in presence of K2CO3 for 12 h. (Schemes 10 and 11)








Scheme 12





Scheme 13



Synthesis of phthalimido and naphthalimido linked phenazine conjugates 48a-h has been carried out by employing N-(p-chlorophenyl)-o-phenylenediamine 45, which has been obtained by reacting o-chloronitrobenzene 42 with p-chloroaniline 43 in presence of K2CO3 in DMF. The product 44 obtained is then reduced to 45 using SnCl2.2H2O in methanol. The oxidation of 45 in presence of FeCl3.6H2O gave the product 46 which on refluxing with 1-(2-aminoethyl)piperazine in dioxane gave the product 47, this on refluxing with 41a-h in acetonitrile in presence of K2CO3 gave the desired products 48a-h as illustrated in Scheme 12 and Scheme 13.

All the compounds (48a–h) were evaluated for antimycobacterial activity against three different Mycobacteria (M. tuberculosis ATCC 27294, M. avium ATCC 49601 and M. intracellulare ATCC 13950) species at a concentration of 50, 25 and 12.5 g by diffusion assay. Compounds 48c, 48d and 48h demonstrated good to mild inhibition of the mycobacterium cultures. Minimum inhibitory concentration (MIC) was recorded as the highest dilution of the compounds that completely inhibited the growth. Compounds 48c and 48d having phthalimide linked phenazines were the most active compounds with an MIC value of 1.0 g/mL against the sensitive strain of M. tuberculosis and an MIC value of 1.0–4.0 g/mL against drug resistant clinical isolates of M. tuberculosis. Compound 48h having naphthalimide linked phenazines demonstrated poor activity (MIC 8.0–16.0 g/mL) against sensitive and resistant strains of M. tuberculosis. None of the compounds were found to have significant activity against M. avium and M. intracellulare cultures.
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